GlassScriptPhysician profile
David M Rivas
NPI 1407836794
$15,542.07
in general payments reported to CMS, 2019-2025
42 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,748 · 2022: $2,224 · 2023: $4,665 · 2024: $4,577 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,569.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,001.14 | 2021-2025 | Epclusa, Veklury, Descovy |
| Abbvie INC. | $1,753.32 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,486.19 | 2021-2025 | Fasenra, Farxiga, Airsupra |
| Abbott Laboratories | $1,180.72 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Viiv Healthcare Company | $1,154.88 | 2022-2025 | Apretude, Cabenuva, Dovato |
| United Therapeutics Corporation | $822.59 | 2021-2024 | Tyvaso |
| Glaxosmithkline, LLC. | $707.64 | 2022-2024 | Arexvy |
| Grifols USA, LLC | $625.97 | 2021-2024 | Prolastin-C Liquid |
| Emd Serono, INC. | $496.98 | 2023-2025 | Serostim, Mavenclad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.15 | 2022-2023 | Xifaxan |
| Incyte Corporation | $250.41 | 2021-2022 | |
| Janssen Biotech, INC. | $250.39 | 2024-2025 | Tremfya, Stelara |
| Idorsia Pharmaceuticals US INC | $250.00 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.55 | 2021-2024 | Jardiance |
| Amgen INC. | $243.62 | 2023 | Repatha, Tavneos |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.